Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are first-line drugs for lung cancers with activating EGFR mutations. Although first- and second-generation EGFR-TKIs were standard first-line treatments, acquired resistance (AR) to these drugs is almost inevitable. Cell line...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohara, Shuta, Suda, Kenichi, Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915563/
https://www.ncbi.nlm.nih.gov/pubmed/33572269
http://dx.doi.org/10.3390/cells10020354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915563/
https://www.ncbi.nlm.nih.gov/pubmed/33572269
http://dx.doi.org/10.3390/cells10020354

Ejemplares similares